You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Mounting evidence suggests that right ventricular pacing is associated with a variety of detrimental effects. Most notably, unnecessary right ventricular pacing can lead to an increase of 8% risk of heart failure death per 10% increase in right ventricular pacing.1 Furthermore, right ventricular pacing is associated with a 1% increase in risk of AF for each 1% increase in cumulative right ventricular pacing.2
Managed Ventricular Pacing (MVP™) reduces unnecessary right ventricular pacing by 99%.3
Reducing unnecessary ventricular pacing has been shown to improve clinical outcomes by reducing the risks of atrial fibrillation (AF)2, 4-6 and heart failure hospitalisation (HFH).2,4
The Managed Ventricular Pacing (MVP) modes promote intrinsic conduction by reducing unnecessary right ventricular pacing. These modes provide atrial-based pacing with ventricular backup. If AV conduction is lost, the device is designed to switch to DDDR or DDD mode. Periodic conduction checks are performed, and if AV conduction resumes, the device switches back to AAIR or AAI mode.
For detailed information regarding this algorithm, visit MedtronicAcademy.com. This feature can be found in some Medtronic Pacemaker, ICD, and CRT-D devices.
Udo E, et al. Int J Cardiol. 2015;185:95-100.
Sweeney MO, et al. Circulation. 2003;107:2932-2937.
Gillis AM, Pürerfellner H, Israel CW, et al. Reduction of unnecessary right ventricular pacing due to the managed ventricular pacing (MVP) mode in patients with symptomatic bradycardia. Benefit for both sinus node disease and AV block indications. Presented at HRS 2005 (Abstract AB21-1).
Anderson HR, Nielsen JC, Thomsen PEB, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. 1997;350:1210-1216.
Skanes AC, et al. J Am Coll Cardiol. 2001;38:167-172.
Neilsen J, et al. J Am Col Cardiol. 2003;42:614-623.